MAP Pharmaceuticals announced updates on the progress of its Phase 3 development program of Levadex (dihydroergotamine (DHE)), for the acute treatment of migraine.  Specifically, it stated that over 400 patients had completed at least six months of treatment and over 200 patients had completed over twelve months of treatment in its open-label safety trial.  No drug-related serious adverse events have been reported. Additionally, MAP Pharmaceuticals announced details of its QT interval trial as well as completed enrollment for both its Pharmacokinetics (PK) and Pharmacodynamics (PD) trials. 

Levadex is an orally inhaled migraine therapy designed to provide both fast onset of action and sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.

For more information call (650) 386-3100 or visit www.mappharma.com.